ArticleBMC cancer2023
Salidroside regulates tumor microenvironment of non-small cell lung cancer via Hsp70/Stub1/Foxp3 pathway in Tregs.
Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Targeting the fibrosis-inflammation-oxidative stress axis: multifaceted mechanisms of salidroside in chronic organ fibrosis.Apoptosis : an international journal on programmed cell death · 2026Review
- Salidroside ameliorates skin aging in male mice by promoting collagen regeneration via modulation of FOS and MMP9.Biogerontology · 2026Article
- Salidroside-Based Nanomedicines for Triple-Negative Breast Cancer: From Molecular Mechanisms to Clinical Translation.Breast cancer (Dove Medical Press) · 2026Review
- miR-1343-3p regulating OGDHL/PDHB-pyruvate glucose metabolic reprogramming against gastric cancer cell proliferation.Discover oncology · 2025Article
- Mendelian randomization analysis unveils causal associations between immune cells, metabolites, and lung cancer risk.Discover oncology · 2025Article
- Salidroside and inflammation-linked disorders: integrative insights into the pharmacological effects and mechanistic targets.Inflammopharmacology · 2025Review
- Advances in Lung Cancer Treatment: Integrating Immunotherapy and Chinese Herbal Medicines to Enhance Immune Response.Chinese journal of integrative medicine · 2025Review
- Integration of active ingredients from traditional Chinese medicine with nano-delivery systems for tumor immunotherapy.Journal of nanobiotechnology · 2025Review
- Sennoside A represses the malignant phenotype and tumor immune microenvironment of non-small cell lung cancer cells by inhibiting the TRAF6/NF-κB pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Traditional Chinese medicine in lung cancer treatment.Molecular cancer · 2025Review
- Salidroside Enhances the Sensitivity of Lung Cancer Cells to Paclitaxel by Regulating the Wnt/β-catenin Signaling Pathway.Current medical science · 2025Article
- The dual-function of HSP70 in immune response and tumor immunity: from molecular regulation to therapeutic innovations.Frontiers in immunology · 2025Review
- Modified Sijunzi Decoction Inhibits Pancreatic Cancer Progression and Improves Immune Suppression: Network Pharmacology and Experimental Validation.Drug design, development and therapy · 2025Article
- Rewiring immune suppression in NSCLC: Roles and plasticity of Tregs and Th17 cells.Frontiers in immunology · 2025Review
- Bioactive components and delivery strategies of food-medicine homologous substances in lung cancer therapy: current advances and clinical translation.Frontiers in nutrition · 2025Review
- Salidroside exerts anti-tumor effects in ovarian cancer by inhibiting STAT3/c-Myc pathway-mediated glycolysis.Biomolecules & biomedicine · 2024Article
- Drug resistance and tumor immune microenvironment: An overview of current understandings (Review).International journal of oncology · 2024Review
- Mechanism of salidroside in tumor suppression through the miRNA-mRNA signaling axis.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe treatment of non-small cell lung cancer (NSCLC) is challenging due to immune tolerance and evasion. Salidroside (SAL) is an extract in traditional Chinese medicine and has a potential antitumor effect. However, the mechanism of SAL in regulating the immunological microenvironment of NSCLC is yet to be clarified.
methodsThe mouse model with Lewis lung cancer cell line (3LL) in C57BL/6 mice was established. And then, the percentage of tumor-infiltrating T cell subsets including Treg was detected in tumor-bearing mice with or without SAL treatment. In vitro, the effect of SAL on the expression of IL-10, Foxp3 and Stub1 and the function of Treg were detected by flow cytometry. Network pharmacology prediction and molecular docking software were used to predict the target of SAL and intermolecular interaction. Furthermore, the effect of SAL on the expression of Hsp70 and the co-localization of Stub1-Foxp3 in Treg was confirmed by flow cytometry and confocal laser microscopy. Finally, Hsp70 inhibitor was used to verify the above molecular expression.
resultsWe discovered that SAL treatment inhibits the growth of tumor cells by decreasing the percentage of tumor-infiltrated CD4
conclusionsSAL inhibits tumor growth by regulating the Hsp70/stub1/Foxp3 pathway in Treg to suppress the function of Treg. It is a new mechanism of SAL for antitumor therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.